Evidence map›Paper›PMID 33097660›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2020

SARS-CoV-2 Orf6 hijacks Nup98 to block STAT nuclear import and antagonize interferon signaling.

Lisa Miorin, Thomas Kehrer, Maria Teresa Sanchez-Aparicio, Ke Zhang, Phillip Cohen, Roosheel S Patel, Anastasija Cupic, Tadashi Makio, Menghan Mei, Elena Moreno and 17 more

Open access · hybridAbstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 386 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
386citing papers in PubMed, 1 pooled it
11.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

386 citing papers in PubMed, 1 synthesis or guideline pooled it, 557 citations in OpenAlex.

  1. Pooled it
  2. The diverse functions of viral microproteins.bioRxiv : the preprint server for biology · 2026
    Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Genetic and chemical correction of cystic fibrosis reduces airway susceptibility to SARS-CoV-2.American journal of physiology. Lung cellular and molecular physiology · 2026
    Article
  15. Review
  16. Article
  17. Review
  18. Article
  19. Review
  20. Article

326 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors at 6 institutions in 2 countries.

Lisa MiorinDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029; lisa.miorin@mssm.edu adolfo.garcia-sastre@mssm.edu.ORCID 0000-0003-0989-3178
Thomas KehrerDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029.
Maria Teresa Sanchez-AparicioDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029.ORCID 0000-0001-6556-5924
Ke ZhangDepartment of Cell Biology, University of Texas Southwestern Medical Center, Dallas, TX 75390.ORCID 0000-0001-5365-3142
Phillip CohenDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029.ORCID 0000-0002-9368-5154
Roosheel S PatelDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029.
Anastasija CupicDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029.ORCID 0000-0002-1291-1042
Tadashi MakioDepartment of Cell Biology, University of Alberta, Edmonton, AB T6G 2H7, Canada.
Menghan MeiDepartment of Biochemistry, Vanderbilt University School of Medicine, Nashville, TN 37232.ORCID 0000-0001-7130-4659
Elena MorenoDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029.
Oded DanzigerDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029.ORCID 0000-0003-0533-3851
Kris M WhiteDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029.
Raveen RathnasingheDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029.
Melissa UccelliniDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029.
Shengyan GaoDepartment of Cell Biology, University of Texas Southwestern Medical Center, Dallas, TX 75390.ORCID 0000-0002-1281-8753
Teresa AydilloDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029.ORCID 0000-0003-3086-1058
Ignacio MenaDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029.ORCID 0000-0001-5464-7086
Xin YinImmunity and Pathogenesis Program, Infectious and Inflammatory Disease Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA 92037.ORCID 0000-0003-2357-6718
Laura Martin-SanchoImmunity and Pathogenesis Program, Infectious and Inflammatory Disease Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA 92037.
Nevan J KroganDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029.
Sumit K ChandaImmunity and Pathogenesis Program, Infectious and Inflammatory Disease Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA 92037.
Michael SchotsaertDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029.
Richard W WozniakDepartment of Cell Biology, University of Alberta, Edmonton, AB T6G 2H7, Canada.ORCID 0000-0003-2328-0247
Yi RenDepartment of Biochemistry, Vanderbilt University School of Medicine, Nashville, TN 37232.ORCID 0000-0003-4531-0910
Brad R RosenbergDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029.ORCID 0000-0002-5885-1276
Beatriz M A FontouraDepartment of Cell Biology, University of Texas Southwestern Medical Center, Dallas, TX 75390.ORCID 0000-0001-8468-5315
Adolfo García-SastreDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029; lisa.miorin@mssm.edu adolfo.garcia-sastre@mssm.edu.ORCID 0000-0002-6551-1827
Icahn School of Medicine at Mount Sinai · USSanford Burnham Prebys Medical Discovery Institute · USThe University of Texas Southwestern Medical Center · USUniversity of Alberta · CAVanderbilt University · USGladstone Institutes · US

Funding

Project 3 - Ex vivo immune profiling of dengue viruses and vaccinesU19AI118610 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI GARCIA-SASTRE, ADOLFO · 2015 to 2021
$46.6M
SARS-CoV adaptations through a Systems Biology Lens (SYBIL)U19AI135972 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Adolfo Garcia-Sastre · 2018 to 2026
$27.2M
RESEARCH PROJECT 2U19AI135990 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Nevan J Krogan · 2018 to 2026
$21.4M
Virulence Factor at the Interface of Viral and Cellular mRNA Nuclear ExportR01AI154635 · NIAID · UT SOUTHWESTERN MEDICAL CENTER · PI Beatriz MA Fontoura · 2020 to 2026
$5.1M
Mechanisms and Regulation of Nuclear mRNA ExportR35GM133743 · NIGMS · VANDERBILT UNIVERSITY · PI Yi Ren · 2019 to 2026
$3.6M
NIAID NIH HHS HHSN272201400008CNIAID NIH HHS R01 AI154635NIAID NIH HHS U19 AI118610NIAID NIH HHS U19 AI135972NIAID NIH HHS U19 AI135990NIGMS NIH HHS R35 GM133743NIH HHS 5R35GM133743
6 · The paper itself

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of the ongoing coronavirus disease 2019 (COVID-19) pandemic that is a serious global health problem. Evasion of IFN-mediated antiviral signaling is a common defense strategy that pathogenic viruses use to replicate and propagate in their host. In this study, we show that SARS-CoV-2 is able to efficiently block STAT1 and STAT2 nuclear translocation in order to impair transcriptional induction of IFN-stimulated genes (ISGs). Our results demonstrate that the viral accessory protein Orf6 exerts this anti-IFN activity. We found that SARS-CoV-2 Orf6 localizes at the nuclear pore complex (NPC) and directly interacts with Nup98-Rae1 via its C-terminal domain to impair docking of cargo-receptor (karyopherin/importin) complex and disrupt nuclear import. In addition, we show that a methionine-to-arginine substitution at residue 58 impairs Orf6 binding to the Nup98-Rae1 complex and abolishes its IFN antagonistic function. All together our data unravel a mechanism of viral antagonism in which a virus hijacks the Nup98-Rae1 complex to overcome the antiviral action of IFN.

Indexed as

Active Transport, Cell NucleusAnimalsBinding SitesChlorocebus aethiopsCOVID-19HEK293 CellsHumansInterferonsNuclear Matrix-Associated ProteinsNuclear PoreNuclear Pore Complex ProteinsNucleocytoplasmic Transport ProteinsProtein BindingSignal TransductionSTAT1 Transcription FactorSTAT2 Transcription FactorInterferonsNuclear Matrix-Associated ProteinsNuclear Pore Complex ProteinsNucleocytoplasmic Transport ProteinsNup98 protein, humanORF6 protein, SARS-CoV-2RAE1 protein, humanSTAT1 protein, humanSTAT1 Transcription FactorSTAT2 protein, humanSTAT2 Transcription FactorViral Proteinsinterferon signaling antagonismNup98ORF6SARS-CoV-2STATs

Identifiers

PMID33097660
PMCPMC7668094
OpenAlexW3094558943

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.